Yu Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu Fu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Xiaobai He
School of Laboratory Medicine and Bioengineering Hangzhou Medical College Hangzhou China
3 shared publicationsFei Kong
School of Laboratory Medicine and Bioengineering Hangzhou Medical College Hangzhou China
2 shared publications- Jianxin Lyu
Laboratory Medicine Center, Department of Clinical Laboratory, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, China
2 shared publications Liang Chen
School of Laboratory Medicine and Bioengineering Hangzhou Medical College Hangzhou China
2 shared publications- Linjie Chen
School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou 311399, China
2 shared publications Quan Fang
Department of laboratory, Physical Examination Center Air Force Hangzhou Special Service Convalescence Center Zone 1 Hangzhou China
2 shared publications
Latest Publications
Rapid identification of SARS‐CoV‐2 variants using stable high‐frequency mutation sites
Respiratory infectious viruses, including SARS-CoV-2, undergo rapid genetic evolution, resulting in diverse subtypes with complex mutations. Detecting and differentiating these subtypes pose significant challenges in respiratory virus surveillance. To address these challenges, we integrated ARMS-PCR with molecular beacon probes, allowing selective amplification and discrimination of subtypes based on adjacent mutation sites. The method exhibited high specificity and sensitivity, detecting as low as 104 copies/mL via direct fluorescence analysis and ~106 copies/mL using real-time PCR. Our robust detection approach offers a reliable and efficient solution for monitoring evolving respiratory infections, aiding early diagnosis and control measures. Further research could extend its application to other respiratory viruses and optimize its implementation in clinical settings.
Rapid identification of SARS‐CoV‐2 variants using stable high‐frequency mutation sites
Respiratory infectious viruses, including SARS-CoV-2, undergo rapid genetic evolution, resulting in diverse subtypes with complex mutations. Detecting and differentiating these subtypes pose significant challenges in respiratory virus surveillance. To address these challenges, we integrated ARMS-PCR with molecular beacon probes, allowing selective amplification and discrimination of subtypes based on adjacent mutation sites. The method exhibited high specificity and sensitivity, detecting as low as 104 copies/mL via direct fluorescence analysis and ~106 copies/mL using real-time PCR. Our robust detection approach offers a reliable and efficient solution for monitoring evolving respiratory infections, aiding early diagnosis and control measures. Further research could extend its application to other respiratory viruses and optimize its implementation in clinical settings.
- Open Access
- 19 July 2023
- Published by Wiley
Rapid Identification of Respiratory Infectious Disease Viruses Using Stable High-Frequency Mutation Sites
Background: Respiratory infectious viruses, such as the novel coronavirus SARS-CoV-2, are highly transmissible and undergo rapid genetic evolution, which leads to the emergence of multiple subtypes with diverse mutation patterns. However, detecting and differentiating between these subtypes present significant challenges in the field of respiratory virus surveillance. Methods: To address these challenges, we developed a novel detection approach that integrates amplification refractory mutation system PCR (ARMS-PCR) with molecular beacon probes. The ARMS-PCR primers were designed to selectively amplify specific subtypes by targeting adjacent mutation sites, while the molecular beacon probes allowed for further discrimination of the amplified products. This combined approach effectively addressed the issues of non-specific binding and improved detection accuracy. Results: Our method demonstrated high specificity and sensitivity in the identification and differentiation of respiratory virus subtypes. Using real-time fluorescence PCR, we achieved a detection limit of approximately 106 copies/mL. Moreover, through the direct analysis of fluorescence signals, we further enhanced the sensitivity to a detection limit of 104 copies/mL. This robust and accurate detection approach is capable of identifying and differentiating between respiratory virus subtypes, including those with complex mutation patterns. Conclusions: The integration of ARMS-PCR and molecular beacon probes is a reliable and efficient solution for the rapid and precise monitoring of evolving respiratory infectious diseases, and it has the potential to facilitate early diagnosis and effective control measures. Further research is needed to expand the application of this detection method to other respiratory viruses and optimize its workflow for clinical and public health settings.
- 19 July 2023
- Published by Wiley
Open AccessRapid Identification of Respiratory Infectious Disease Viruses Using Stable High-Frequency Mutation Sites
Background: Respiratory infectious viruses, such as the novel coronavirus SARS-CoV-2, are highly transmissible and undergo rapid genetic evolution, which leads to the emergence of multiple subtypes with diverse mutation patterns. However, detecting and differentiating between these subtypes present significant challenges in the field of respiratory virus surveillance. Methods: To address these challenges, we developed a novel detection approach that integrates amplification refractory mutation system PCR (ARMS-PCR) with molecular beacon probes. The ARMS-PCR primers were designed to selectively amplify specific subtypes by targeting adjacent mutation sites, while the molecular beacon probes allowed for further discrimination of the amplified products. This combined approach effectively addressed the issues of non-specific binding and improved detection accuracy. Results: Our method demonstrated high specificity and sensitivity in the identification and differentiation of respiratory virus subtypes. Using real-time fluorescence PCR, we achieved a detection limit of approximately 106 copies/mL. Moreover, through the direct analysis of fluorescence signals, we further enhanced the sensitivity to a detection limit of 104 copies/mL. This robust and accurate detection approach is capable of identifying and differentiating between respiratory virus subtypes, including those with complex mutation patterns. Conclusions: The integration of ARMS-PCR and molecular beacon probes is a reliable and efficient solution for the rapid and precise monitoring of evolving respiratory infectious diseases, and it has the potential to facilitate early diagnosis and effective control measures. Further research is needed to expand the application of this detection method to other respiratory viruses and optimize its workflow for clinical and public health settings.
- 17 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28953
Verifying AXL and putative proteins as SARS‐CoV‐2 receptors by DnaE intein‐based rapid cell–cell fusion assay
As the understanding of the mechanisms of SARS‐CoV‐2 infection continues to grow, researchers have come to realize that ACE2 and TMPRSS2 receptors are not the only way for the virus to invade the host, and that there are many molecules that may serve as potential receptors or cofactors. The functionality of these numerous receptors, proposed by different research groups, demands a fast, simple, and accurate validation method. To address this issue, we here established a DnaE intein‐based cell‐cell fusion system, a key result of our study, which enables rapid simulation of SARS‐CoV‐2 host cell infection. This system allowed us to validate that proteins such as AXL function as SARS‐CoV‐2 spike protein receptors and synergize with ACE2 for cell invasion, and that proteins like NRP1 act as cofactors, facilitating ACE2‐mediated syncytium formation. Our results also suggest that mutations in the NTD of the SARS‐CoV‐2 Delta variant spike protein show a preferential selection for Spike‐AXL interaction over Spike‐LDLRAD3. In summary, our system serves as a crucial tool for the rapid and comprehensive verification of potential receptors, screening of SARS‐CoV‐2–neutralizing antibodies, or targeted drugs, bearing substantial implications for translational clinical applications.
- 17 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28953
Verifying AXL and putative proteins as SARS‐CoV‐2 receptors by DnaE intein‐based rapid cell–cell fusion assay
As the understanding of the mechanisms of SARS‐CoV‐2 infection continues to grow, researchers have come to realize that ACE2 and TMPRSS2 receptors are not the only way for the virus to invade the host, and that there are many molecules that may serve as potential receptors or cofactors. The functionality of these numerous receptors, proposed by different research groups, demands a fast, simple, and accurate validation method. To address this issue, we here established a DnaE intein‐based cell‐cell fusion system, a key result of our study, which enables rapid simulation of SARS‐CoV‐2 host cell infection. This system allowed us to validate that proteins such as AXL function as SARS‐CoV‐2 spike protein receptors and synergize with ACE2 for cell invasion, and that proteins like NRP1 act as cofactors, facilitating ACE2‐mediated syncytium formation. Our results also suggest that mutations in the NTD of the SARS‐CoV‐2 Delta variant spike protein show a preferential selection for Spike‐AXL interaction over Spike‐LDLRAD3. In summary, our system serves as a crucial tool for the rapid and comprehensive verification of potential receptors, screening of SARS‐CoV‐2–neutralizing antibodies, or targeted drugs, bearing substantial implications for translational clinical applications.